Letter |

Open letter to Janssen on reducing the price of bedaquiline

MSF joins civil society and many other groups in asking Janssen to reduce the price of their new TB medicine, bedaquiline, which is the first new TB drug to receive approval in 40 years. The drug is currently approved to treat patients with the deadliest form of drug-resistant tuberculosis, XDR-TB, but the current pricing structure is prohibitive, particularly for middle-income countries.